

**Now Virtual!**

## **USP Workshop on Therapeutic Peptides and Oligonucleotides**

# **Regulations and Quality Standards**

**March 1st, 3rd, and 5th, 2021  
10am – 1pm EST**



## **Call for Abstracts**

**Deadline for Submission December 1, 2020**



We are pleased to invite you to submit abstracts for oral presentations or posters at the USP Workshop on Therapeutic Peptides and Oligonucleotides: Regulations and Quality Standards to be held virtually on **March 1st, 3rd, and 5th, 2021**, from 10am – 1pm each day.

**The Steering Committee is accepting abstracts for presentations on the following topics for either peptides or oligonucleotides:**

- Raw materials for drug substance
  - Setting specifications
  - Identification and characterization of impurities in raw materials
  - Performance testing to demonstrate fit-for-purpose
  - Developing stability-indicating assays
  - Quality systems
  - Supplier risk management
  - Case studies sharing successes, failures and lessons learned due to raw material issues
- Drug products
  - Novel formulation approaches
  - Novel delivery systems

- Molecular design: improving stability, bioavailability, half-life extension
- Analytical development, characterization and validation
  - Modifying analytical techniques/sample preparation to support testing of complex drug products
  - Case studies demonstrating successful validation and use of sophisticated technologies for release testing (e.g., mass spectrometry, NMR, etc.)
  - Advanced orthogonal technologies for characterization
  - Bridging between old and new methods
  - Identifying and characterizing impurities in raw materials, drug substances and drug products
  - Bioassay development
- Green chemistry approaches for synthesis and/or analysis
- Advances in manufacturing and purification technologies: strategies and novel methods
- Control strategies
  - Setting specifications and acceptance criteria
  - Comparability between generics and innovator products, including special cases of recombinant to synthetic peptides
  - Peptide-related immunogenicity testing (in-silico, in-vitro, in-vivo)
  - Current and future documentary standards and reference standard materials to support peptides and oligonucleotides
- Regulatory aspects
  - Compliance
- CMC strategies
  - Case studies demonstrating successful regulatory submissions or addressing gaps following review
- Drug conjugates
- Personalized medicines
  - Peptide vaccines
  - Oligonucleotides

- Structure-function studies and new targets

#### **Contributed abstract/poster submission timeline:**

- **Submission deadline:** For oral presentations, please submit abstracts by December 1, 2020. For posters, we will continue to accept poster presentations on a rolling basis (priority review will be given for early submissions).
- **Notification of acceptance/denial:** Notification will be sent beginning in December 2020.

#### **Submission instructions:**

##### **1. Submit your abstract**

Send your abstract submission to: Maura Kibbey at [mck@usp.org](mailto:mck@usp.org) **Your abstract must include your full contact information: presenter's name, title, company, email address, and telephone number.** If there are multiple authors on the abstract, please indicate one person who will be the presenter. Please also indicate if you are applying to be a speaker or poster presenter.

##### **2. Financial considerations for approved presenters**

Complimentary workshop registration will be provided for all session speakers and graduate student poster presenters. A discounted registration fee will be offered for other poster presenters.

##### **3. Assistance**

If you have any questions or are experiencing difficulties in the submission process, please contact:

Maura Kibbey

Senior Scientific Fellow, USP Global Biologics

Email: [mck@usp.org](mailto:mck@usp.org)